On October 23, 2024, the Advisory Committee on Immunization Practices (ACIP) updated its recommendations for receipt of COVID-19 vaccines. In addition to its previous recommendations for 2024-2025 vaccines, ACIP recommends (1):

A second dose* of 2024-2025 COVID-19 vaccine for adults ages 65 years and older
A second dose† of 2024-2025 COVID-19 vaccine for people ages 6 months to 64 years who are moderately or severely immunocompromised
Additional doses (i.e., 3 or more doses) of 2024-2025 COVID-19 vaccine for people ages 6 months and older who are moderately or severely immunocompromised, under shared clinical decision making

*If previously unvaccinated and receiving Novavax, 2 doses are recommended as initial vaccination series followed by a third dose of any age-appropriate 2024-2025 COVID-19 vaccine 6 months (minimum interval 2 months) after second dose.1

†If previously unvaccinated or receiving initial vaccination series, a multidose vaccination series with an age-appropriate 2024- 2025 vaccine is recommended. This additional 2024-2025 vaccine dose is recommended 6 months (minimum interval 2 months) after completion of initial vaccination series.1

The Director of the Centers for Disease Control and Prevention has adopted these recommendations and has made them official.

We support your efforts to help protect vaccine-eligible patients from COVID-19. Please consider ACIP’s updated recommendations when identifying vaccine-eligible patients and forecasting demand for vaccines and talk with us about ensuring that you have an adequate stock of 2024-2025 formula COVID- 19 vaccines.

Reference:

(1) Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States. Updated October 31, 2024. Accessed November 1, 2024. https://www.cdc.gov/vaccines/covid-19/clinical- considerations/interim-considerations-us.html